8-K: Kewaunee Scientific Reports Strong Sales Growth in Q2 FY26

Kewaunee Scientific Corporation announced its second quarter fiscal year 2026 results, reporting a significant increase in sales driven by the Nu Aire acquisition, despite a decline in net earnings.

Summary

• Sales for the second quarter of fiscal year 2026 increased by 46.8% to $70,096,000, compared to $47,764,000 in the prior year's second quarter.
• Pre-tax earnings for the quarter decreased by 12.2% to $3,453,000, down from $3,931,000 in the prior year quarter.
• Net earnings were $2,445,000, a decrease from $3,008,000 in the prior year quarter.
• Diluted earnings per share were $0.82, compared to $1.01 in the prior year quarter.
• EBITDA for the quarter increased to $5,790,000 from $4,883,000 in the prior year quarter.
• The company's order backlog stood at $192.9 million on October 31, 2025, an increase from $184.4 million on October 31, 2024, but a decrease from $214.6 million on April 30, 2025.
• Domestic sales grew by 51.7% to $55,224,000, while international sales increased by 31.0% to $14,872,000.
• Cash on hand on October 31, 2025, was $13,679,000, a decrease from $17,164,000 on April 30, 2025.
• Working capital improved to $67,830,000 on October 31, 2025, from $64,651,000 on April 30, 2025.
• Long-term debt decreased to $58,164,000 on October 31, 2025, from $60,730,000 on April 30, 2025.
• The debt-to-equity ratio improved to 0.88-to-1 on October 31, 2025, from 0.99-to-1 on April 30, 2025.

Sentiment

Score: 6

Explanation: The company demonstrated strong sales growth, driven by a successful acquisition, and improved its balance sheet. However, the decline in net earnings and diluted EPS, coupled with anticipated project delivery volatility, presents a mixed financial picture. Strategic positioning for future growth is positive, but current profitability is a concern.

Positives

• Total sales increased by 46.8% year-over-year to $70,096,000, demonstrating strong top-line growth.
• EBITDA increased to $5,790,000 from $4,883,000 in the prior year quarter, indicating improved operational profitability.
• International segment sales grew by 31.0% to $14,872,000, with net earnings increasing to $641,000 from $356,000, driven by continued delivery of large projects.
• The Nu Aire, Inc. acquisition contributed significantly, with strong financial performance helping to offset volatility in the legacy business.
• Order backlog remains strong at $192.9 million, near record levels, particularly for the Domestic segment, providing future revenue visibility.
• Corporate segment EBITDA improved year-over-year, largely due to lower acquisition-related costs compared to the prior year.
• Long-term debt decreased to $58,164,000, and the debt-to-equity ratio improved to 0.88-to-1, strengthening the balance sheet.

Negatives

• Pre-tax earnings decreased by 12.2% to $3,453,000, despite significant sales growth.
• Net earnings declined to $2,445,000 from $3,008,000 in the prior year quarter.
• Diluted earnings per share decreased to $0.82 from $1.01 in the prior year quarter.
• Domestic segment profitability was impacted by lower manufacturing volumes across the laboratory construction portion of the business.
• Cash on hand decreased to $13,679,000 on October 31, 2025, from $17,164,000 on April 30, 2025.

Risks

• Ability to realize the full benefits anticipated from the Nu Aire acquisition.
• Competitive and general economic conditions, including disruptions from government mandates, both domestically and internationally.
• Supplier constraints and other supply disruptions impacting operations.
• Changes in customer demands affecting sales and project timelines.
• Technological changes in operations or the industry requiring adaptation.
• Dependence on customers' required delivery schedules, leading to volatility in project timelines.
• Risks related to fluctuations in operating results from quarter to quarter.
• Risks associated with international operations, including foreign currency fluctuations.
• Changes in the legal and regulatory environment impacting business.
• Changes in raw materials and commodity costs affecting profitability.
• Acts of terrorism, war, governmental action, natural disasters, and other Force Majeure events.

Future Outlook

Management anticipates continued volatility in project delivery timelines for the remainder of the fiscal year. However, they remain confident in the demand for products and the strength of the markets served, expecting the backlog to remain strong through the end of the fiscal year, positioning the company for continued success in fiscal year 2027. Strategic investments in the Corporate platform are ongoing to support future anticipated growth.

Management Comments

• "As discussed in our prior earnings release, we expect volatility in project delivery timelines for the balance of the fiscal year and we saw that begin in quarter 2."
• "Our quoting and booking activity remain strong, which is reflected in our backlog that remains near record levels, specifically for our Domestic segment."
• "Nu Aire had strong financial performance in the quarter, which helped to offset this volatility in the legacy business, which is more tied to the construction market."
• "This dynamic illustrates our strategy, which we recently launched with the acquisition of Nu Aire, to diversify through well-targeted acquisitions. This strategy will also allow us to provide a broader set of laboratory solutions to the market."
• "While we still expect volatility in project delivery timing for the balance of this fiscal year, we remain confident in the demand for our products and the strength of the markets we serve."
• "Our current quoting activity gives us confidence that our backlog will remain strong through the end of the fiscal year, setting the company up for continuing success in fiscal 2027."
• "Kewaunee's early repayment of the Seller Notes strengthens our balance sheet, positions us for further inorganic growth, and underscores our commitment to long-term value creation."

Industry Context

Kewaunee Scientific operates in the specialized market of laboratory, healthcare, and technical furniture. The acquisition of Nu Aire, a manufacturer of biological safety cabinets and other essential laboratory products, represents a strategic move to diversify the company's offerings and provide a broader set of laboratory solutions. This aligns with a broader industry trend towards integrated solutions and expanding product portfolios to capture more market share in the growing life sciences and healthcare sectors. The mention of volatility in project delivery timelines and ties to the construction market indicates sensitivity to macroeconomic conditions affecting infrastructure and facility development.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess performance against global benchmarks. Therefore, a direct comparison to industry standards is not feasible based solely on the provided information.

Stakeholder Impact

• Shareholders: Mixed impact due to strong sales growth and strategic acquisitions offset by a decline in net earnings and EPS. Long-term value creation is emphasized through balance sheet strengthening and inorganic growth.
• Employees: Strategic investments in people are ongoing as part of building out the Corporate platform.
• Customers: The acquisition of Nu Aire allows the company to provide a broader set of laboratory solutions to the market.
• Creditors: Debt reduction and an improved debt-to-equity ratio indicate a stronger financial position, potentially reducing credit risk.

Next Steps

• Continue strategic investments in people, processes, and technology to build out the Corporate platform to support future anticipated growth.
• Focus on inorganic growth opportunities, leveraging the strengthened balance sheet.
• Manage anticipated volatility in project delivery timing for the balance of the fiscal year.
• Maintain strong quoting activity to ensure backlog remains robust through the end of the fiscal year, setting up for fiscal 2027 success.

Key Dates

Recommendation

The company exhibits strong top-line growth and successful strategic execution with the Nu Aire acquisition, which is performing well and diversifying the business. However, the year-over-year decline in net earnings and diluted EPS, alongside anticipated project delivery volatility, suggests near-term earnings pressure. While the improved balance sheet and robust backlog provide a solid foundation for future growth, the mixed financial performance warrants a 'hold' recommendation rather than a 'buy' or 'sell' at this time, as investors await clearer signs of sustained profitability improvement.

Keywords

Kewaunee Scientific, KEQU, Q2 earnings, financial results, laboratory furniture, healthcare furniture, technical furniture, Nu Aire, biological safety cabinets, EBITDA, backlog, debt-to-equity